Level Zero Health, a UK-based healthtech startup, has raised £5.5 million ($6.9 million) in pre-seed funding, marking the largest amount ever secured by a female-founded company in Europe. The investment, led by Redalpine, will fuel the development of its pioneering remote and continuous hormone monitoring device using unique DNA-based sensors.
Founded by Ula Rustamova, a former Palantir tech lead, and Irene Jia, a medical device expert, Level Zero Health aims to revolutionize hormone testing, offering real-time data via a non-invasive wearable patch. This technology surpasses traditional blood tests by providing continuous hormone level measurements, impacting areas like fertility treatment, menopause management, and stress tracking. Testing has shown a 98% accuracy rate.
Rustamova emphasized the breakthrough, stating the funding will enable them to bring this revolutionary solution to market, making hormone tracking more accessible and insightful. The company, while initially focusing on B2B clinical applications, plans to expand into consumer health and pharmaceutical markets.
Philip Kneis from Redalpine highlighted the potential of continuous hormone measurement, stating that it will transform hormone tracking. Level Zero Health’s innovative approach, using aptamers as the core sensor component, has garnered support from various investors and experts, paving the way for personalized health management.
